Literature DB >> 25219890

Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD).

A M Pfeil1, P Imfeld, R Pettengell, S S Jick, T D Szucs, Christoph R Meier, M Schwenkglenks.   

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in European adults. We aimed to evaluate time trends in CLL incidence and medical resource utilisation of CLL patients in the UK. We conducted a retrospective, observational cohort analysis using the UK Clinical Practice Research Datalink (CPRD) comprising mainly primary care data. We included adult patients with newly diagnosed CLL between January 2000 and June 2012. Descriptive and trend analyses of CLL incidence and medical resource utilisation were performed. A total of 2576 patients with CLL met the eligibility criteria. At diagnosis, the majority of patients (71.7 %) were above 65 years of age. The European age-standardised CLL incidence rate in the CPRD was 6.2/100,000 (95 % confidence interval [CI] 6.0, 6.5/100,000) person-years. There was no statistically significant increase over time. The CLL patients had on average 74.6 general practitioner visits during a median follow-up of 3.3 years. Between 2000 and 2012, the average number of recorded hospitalisations and referrals per year corrected for duration of follow-up significantly (p < 0.001) increased by 8.1 % (95 % CI 6.8 %, 9.3 %) and 16.4 % (95 % CI 15.4 %, 17.3 %), respectively. Referrals and hospitalisations in the second year compared to the first year following the CLL diagnosis significantly decreased. CLL incidence rates in the CPRD were stable over the period from 2000 to 2012. Medical resource utilisation in UK primary care was well documented, but further research is needed to describe secondary and tertiary care medical resource utilisation e.g. chemotherapy administration, which is inadequately captured in the CPRD.

Entities:  

Mesh:

Year:  2014        PMID: 25219890     DOI: 10.1007/s00277-014-2217-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Rates and risk of hospitalisation among patients with type 2 diabetes: retrospective cohort study using the UK General Practice Research Database linked to English Hospital Episode Statistics.

Authors:  J M Khalid; M Raluy-Callado; B H Curtis; K S Boye; A Maguire; M Reaney
Journal:  Int J Clin Pract       Date:  2013-09-23       Impact factor: 2.503

2.  Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray.

Authors:  Jie Li; Yi Qin; Haiyan Zhang
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

3.  Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia.

Authors:  Emelie C Rotbain; Klaus Rostgaard; Michael A Andersen; Caspar Da Cunha-Bang; Carsten U Niemann; Henrik Frederiksen; Henrik Hjalgrim
Journal:  Clin Epidemiol       Date:  2021-12-30       Impact factor: 4.790

4.  Characteristics of chronic lymphocytic leukemia in Senegal.

Authors:  Abibatou Sall; Awa Oumar Touré; Fatimata Bintou Sall; Moussa Ndour; Seynabou Fall; Abdoulaye Sène; Blaise Félix Faye; Moussa Seck; Macoura Gadji; Tandakha Ndiaye Dièye; Claire Mathiot; Sophie Reynaud; Saliou Diop; Martine Raphaël
Journal:  BMC Hematol       Date:  2016-04-23

5.  Should a clinical rotation in hematology be mandatory for undergraduate medical students?

Authors:  Jay Mandan; Harmeet Singh Sidhu; Adil Mahmood
Journal:  Adv Med Educ Pract       Date:  2016-09-13

6.  Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia.

Authors:  Xingjian Li; Daniel T Payne; Badarinath Ampolu; Nicholas Bland; Jane T Brown; Mark J Dutton; Catherine A Fitton; Abigail Gulliver; Lee Hale; Daniel Hamza; Geraint Jones; Rebecca Lane; Andrew G Leach; Louise Male; Elena G Merisor; Michael J Morton; Alex S Quy; Ruth Roberts; Rosanna Scarll; Timothy Schulz-Utermoehl; Tatjana Stankovic; Brett Stevenson; John S Fossey; Angelo Agathanggelou
Journal:  Medchemcomm       Date:  2019-08-01       Impact factor: 3.597

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.